Gapping up
In reaction to strong earnings/guidance: DSKY +12%, GZT +1.4%, NGL +0.6%
M&A news: CLDN +6.1% (co hired Wedbush to seek an acquisition or partnership), ALTR +4.7% (Altera confirms it will be acquired by Intel (INTC) for $54 per share)
Select ASCO presenting names showing strength: ONTY +29.5%, IMGN +19.4%, EXEL +11.4%, VBLT +10.8%, HALO +6.7%, CBLI +5.9%, CTIC +5.2%, RXDX +5.2%, JUNO +4%, OGXI +3.3%, THLD +3.1%, PSTI +2.5%, KPTI +2.2%, BMY +2%, CRIS +1.2%, CLDX +1.1%, CLDX +1.1%
Select China related names showing strength after Shanghai Comp was +4.7% overninght: SFUN +2.2%, LFC +2.1%, YOKU +2%, FXI +1.7%
Other news: PRAN +19% (announces that the EC has approved orphan designation for PBT2 for the treatment of Huntington's disease), HERO +13.7% (received a notice from Saudi Aramco withdrawing the previously issued notice of termination with respect to the contract for the Hercules 261 and declaring that all terms and conditions of the contract remain in full force and effect), CYTX +8.9% (enters into a four year, $17.7 mln term loan with Oxford Finance), MDCO +7.5% (nnounces the results of its Phase 1 study for ABP-700), BIOC +6.1% (announces receipt of a US Patent for its blood collection and transport preservative Diazolidinyl Urea), IMMU +4.7% (reports complete responses in patients with metastatic triple-negative breast cancer after Sacituzumab Govitecan treatment), ADXS +4.3% (announces FDA clearance of investigational new drug application for phase 2 study of ADXS-HPV), CLF +2.8% (still checking; may still be related to Insider purchases rpted on Friday), HRTX +2.7% (discloses it entered into a 7 year Commercial Manufacturing Services Agreement for SUSTOL with Lifecore Biomedical), OREX+2% (discloses it entered into a supply agreement with Mallinckrodt (MNK) for naltrexone), MDXG +1.7% (traded higher AMC Friday, favorable commentary on Friday's Mad Money), NBG +1.5% (cont vol surrounding Greece), ACHN +1.1% (Point72 Asset Management discloses 5.0% passive stake in 13G filing)
Analyst comments: ANR +16.3% (upgraded to Neutral from Sell at Goldman ), LIFE +5.9% (initiated with a Overweight at JP Morgan), SYN +5.3% ( initiated with an Outperform at William Blair; $12 tgt), FATE +3.8% (initiated with a Outperform at Leerink Partners), PAY +2.3% (upgraded to Outperform from Mkt Perform at Raymond James ), BYD +2.2% (upgraded to Outperform from Neutral at Credit Suisse), COLL +1.4% (initiated with a Buy at Jefferies), C +1.1% (upgraded to Buy from Neutral at Goldman
)
In reaction to strong earnings/guidance: DSKY +12%, GZT +1.4%, NGL +0.6%
M&A news: CLDN +6.1% (co hired Wedbush to seek an acquisition or partnership), ALTR +4.7% (Altera confirms it will be acquired by Intel (INTC) for $54 per share)
Select ASCO presenting names showing strength: ONTY +29.5%, IMGN +19.4%, EXEL +11.4%, VBLT +10.8%, HALO +6.7%, CBLI +5.9%, CTIC +5.2%, RXDX +5.2%, JUNO +4%, OGXI +3.3%, THLD +3.1%, PSTI +2.5%, KPTI +2.2%, BMY +2%, CRIS +1.2%, CLDX +1.1%, CLDX +1.1%
Select China related names showing strength after Shanghai Comp was +4.7% overninght: SFUN +2.2%, LFC +2.1%, YOKU +2%, FXI +1.7%
Other news: PRAN +19% (announces that the EC has approved orphan designation for PBT2 for the treatment of Huntington's disease), HERO +13.7% (received a notice from Saudi Aramco withdrawing the previously issued notice of termination with respect to the contract for the Hercules 261 and declaring that all terms and conditions of the contract remain in full force and effect), CYTX +8.9% (enters into a four year, $17.7 mln term loan with Oxford Finance), MDCO +7.5% (nnounces the results of its Phase 1 study for ABP-700), BIOC +6.1% (announces receipt of a US Patent for its blood collection and transport preservative Diazolidinyl Urea), IMMU +4.7% (reports complete responses in patients with metastatic triple-negative breast cancer after Sacituzumab Govitecan treatment), ADXS +4.3% (announces FDA clearance of investigational new drug application for phase 2 study of ADXS-HPV), CLF +2.8% (still checking; may still be related to Insider purchases rpted on Friday), HRTX +2.7% (discloses it entered into a 7 year Commercial Manufacturing Services Agreement for SUSTOL with Lifecore Biomedical), OREX+2% (discloses it entered into a supply agreement with Mallinckrodt (MNK) for naltrexone), MDXG +1.7% (traded higher AMC Friday, favorable commentary on Friday's Mad Money), NBG +1.5% (cont vol surrounding Greece), ACHN +1.1% (Point72 Asset Management discloses 5.0% passive stake in 13G filing)
Analyst comments: ANR +16.3% (upgraded to Neutral from Sell at Goldman ), LIFE +5.9% (initiated with a Overweight at JP Morgan), SYN +5.3% ( initiated with an Outperform at William Blair; $12 tgt), FATE +3.8% (initiated with a Outperform at Leerink Partners), PAY +2.3% (upgraded to Outperform from Mkt Perform at Raymond James ), BYD +2.2% (upgraded to Outperform from Neutral at Credit Suisse), COLL +1.4% (initiated with a Buy at Jefferies), C +1.1% (upgraded to Buy from Neutral at Goldman
)